Trial
NCT06291415
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Hutchmed
Collaborators
—
Condition
Immune Thrombocytopenia
Intervention
HMPL-523
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-16